Document Detail


Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone.
MedLine Citation:
PMID:  9131395     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic active hepatitis due to HCV represents a severe progressive disorder of the liver, At present, Interferon seems to be the most efficacious treatment available, however, only 20-25% of the patients treated achieve complete remission. The efficacy has, therefore, been evaluated of Ribavirin, a nucleoside analogue active both on DNA and RNA viruses, in the treatment of non responders to a previous course of interferon. Twenty patients were randomly assigned to two groups: A) received the association R (800 mg/day for 2 months)+interferon (9 Mu/week for 6 months); B) received IFN (9 Mu/week for 6 months). All patients completed the study without important side effects. Four patients in group A presented reduced ALT and loss of viraemia during treatment with Ribavirin. Only one patient in group B had reduced indices of cell lysis and was negative for HCV-RNA during the course of the study. However, viremia and an increase of ALT values were observed in all of these subjects once treatment was interrupted. The results emerging from this study indicate that Ribavirin therapy, at the dose and duration of treatment employed, is not sufficient to change the natural course of events of chronic active hepatitis from HCV.
Authors:
G Scotto; V Fazio; G Tantimonaco
Related Documents :
14736075 - Randomized treatment study of inosiplex versus combined inosiplex and intraventricular ...
9893585 - Effects of protease inhibitors on the course of cmv retinitis in relation to cd4+ lymph...
14565605 - Changes in levels of immune activation and reconstitution markers among hiv-1-infected ...
2127785 - Treatment of chronic hepatitis c with recombinant alpha-interferon. a multicentre rando...
22678095 - Influence of a modified nd:yag laser treatment outside the visual axis on the morpholog...
10223485 - Transrectal ultrasound with separate measurement of the transition zone volume predicts...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The Italian journal of gastroenterology     Volume:  28     ISSN:  0392-0623     ISO Abbreviation:  Ital J Gastroenterol     Publication Date:  1996 Dec 
Date Detail:
Created Date:  1997-07-28     Completed Date:  1997-07-28     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8000544     Medline TA:  Ital J Gastroenterol     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  505-11     Citation Subset:  IM    
Affiliation:
Divisione di Malattie Infettive, Ospedali Riuniti, Foggia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alanine Transaminase / blood
Antiviral Agents / administration & dosage,  adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Follow-Up Studies
Hepacivirus / genetics,  immunology
Hepatitis C / enzymology,  pathology,  therapy*
Hepatitis C Antibodies / analysis
Hepatitis, Chronic / enzymology,  pathology,  therapy*
Humans
Interferon Type I, Recombinant / administration & dosage,  adverse effects,  therapeutic use*
Male
Pilot Projects
Polymerase Chain Reaction
RNA, Viral / analysis,  drug effects
Ribavirin / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Hepatitis C Antibodies; 0/Interferon Type I, Recombinant; 0/RNA, Viral; 36791-04-5/Ribavirin; EC 2.6.1.2/Alanine Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Variations in the hypervariable region 1 of the envelope region E2 of hepatitis C virus RNA appear a...
Next Document:  Helicobacter pylori infection in families of Helicobacter pylori-positive children.